SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of continuing on treatment for >24 weeks.

Additional locations may be listed on ClinicalTrials.gov for NCT06239480.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationPalvella Therapeutics, Inc.

Principal InvestigatorJoyce Teng

• Primary IDPALV-09
• Secondary IDsNCI-2025-00641
• ClinicalTrials.gov IDNCT06239480